Navigation Links
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Date:7/7/2009

Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control and low incidence of hypoglycemia when used with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a s
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. Strativas New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
3. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
4. A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis
5. U.S. FDA Accepts Aridol(TM) New Drug Application for Review
6. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
7. ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA
8. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
9. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
10. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
11. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... United States Supreme Court strengthened the case against stem ... ,The answer is yes, according to the California consumer watchdog ... a consensus opinion. , ,The nation's high court, in a ... the Federal Circuit , ruled in favor of KSR International ...
... always been important to the economic growth of a ... traditionally been viewed as transportation - rail, waterways, and ... Today, the definition of infrastructure must also include network ... compete globally. , ,Just as you would not locate ...
... The bioscience industry has become an important force in ... capital it generates through discovery and research, the 30,000 ... those discoveries, and the nearly $8 billion in revenue ... ,Wisconsin bioscience companies have positioned themselves as national and ...
Cached Biology Technology:Supreme Court ruling seen as blow to WARF stem cell patents 2Supreme Court ruling seen as blow to WARF stem cell patents 3States need to be more "connectivity conscious" 2States need to be more "connectivity conscious" 3States need to be more "connectivity conscious" 4Wisconsin biosciences rise to the challenge 2Wisconsin biosciences rise to the challenge 3
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon ... data. Crossmatch is a world leader in multi-factor ... expertise are helping federal agencies and commercial organizations ...   "The vast majority of network ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... ice formation occurred in the Arctic earlier than previously ... week in Nature . "The results are also ... in the Arctic before it did in Antarctica, which ... Richard Pearce of the University of Southampton,s School of ...
... 14, 2009 -- The stress of rising natural gas prices ... homes. For some this means moving towards modern alternative ... traditional method for a solution to these rising costs. ... been reevaluated as a potentially viable option for home heating. ...
... Va.The Journal of Vascular and Interventional Radiology ,s quality ... years, and the increase in its impact factor to 2.217 ... radiology, nuclear medicine and medical imaging journals, according to results ... continues to see a rise in its impact, the Society ...
Cached Biology News:Early initiation of Arctic sea-ice formation 2Early initiation of Arctic sea-ice formation 3Wood stoves -- a viable home heat source? 2Journal of Vascular and Interventional Radiology increases impact, international reach 2Journal of Vascular and Interventional Radiology increases impact, international reach 3
... sequences: Two separate vials containing ... the same sequence used as antigens ... No. 160890) To ... guanylate cyclase polyclonal antiserum (Catalog No. ...
... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
... Primer is designed for sequencing inserts cloned ... V2051, V2061). The primer hybridizes upstream of ... approximately 4050 base pairs upstream of the ... to determine if an insert is cloned ...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Biology Products: